Loading…
Bone Biologics Corporation is projected to decline to $1.21 by 2027, a -2% move from its current price of $1.24. BBLG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.21 | $1.24 | $1.27 | -0.01% |
| May 30 | $1.20 | $1.24 | $1.29 | -0.02% |
| May 31 | $1.19 | $1.24 | $1.30 | -0.03% |
| Jun 1 | $1.18 | $1.24 | $1.30 | -0.04% |
| Jun 2 | $1.17 | $1.24 | $1.31 | -0.05% |
| Jun 3 | $1.16 | $1.24 | $1.32 | -0.06% |
| Jun 4 | $1.16 | $1.24 | $1.33 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.16 | $1.24 | $1.33 | -0.07% |
| Week 2 | $1.12 | $1.24 | $1.36 | -0.14% |
| Week 3 | $1.10 | $1.24 | $1.39 | -0.21% |
| Week 4 | $1.08 | $1.24 | $1.42 | -0.29% |
| Week 5 | $1.06 | $1.24 | $1.44 | -0.36% |
| Week 6 | $1.05 | $1.23 | $1.46 | -0.43% |
| Week 7 | $1.03 | $1.23 | $1.48 | -0.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using a recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications.
It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Bone Biologics Corporation (BBLG) is currently priced at $1.22 per share, with a market capitalization of $2.19M. It is ranked 5471. The long-term price outlook is expressed through a year-by-year forecast that shows a mix of neutral and bullish sentiment across the horizon, with averages progressing from the mid-2020s toward higher levels later in the period.
The forecast lists year-by-year averages such as 2026 avg $1.22, 2027 avg $1.18, 2028 avg $1.24, 2029 avg $1.49, 2030 avg $1.46, 2032 avg $1.50, 2034 avg $1.62, 2035 avg $1.92, 2040 avg $2.24, and 2050 avg $3.64, with corresponding max values up to $6.61 by 2050.
A major floor 12.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
The nearest ceiling, 13.3% above — a clean break opens room to run.
A major ceiling 43.5% above — clearing it would confirm fresh momentum.
Key BBLG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBLG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.24 | Buy | $1.24 | Sell |
| MA 10 | $1.25 | Sell | $1.25 | Sell |
| MA 20 | $1.28 | Sell | $1.27 | Sell |
| MA 50 | $1.26 | Sell | $1.29 | Sell |
| MA 100 | $1.34 | Sell | $1.43 | Sell |
| MA 200 | $1.71 | Sell | $2.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.08 | Neutral |
| Stoch RSI (14) | 37.89 | Neutral |
| CCI (20) | -90.99 | Neutral |
| Williams %R (14) | -78.95 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -5.70 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 21.05 | Neutral |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 38.26 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 1.23 | Buy |
| ADX (14) | 12.09 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is bearish. The RSI(14) is 40, and the price is trading below the 50-day simple moving average ($1.26) and well below the 200-day simple moving average ($1.72). Support is at $1.22 and resistance at $1.40, framing a cautious setup.
The 30-day range runs from $1.03 to $1.45, illustrating limited but ongoing volatility in the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.08 | $1.24 | $1.53 | 0% | Neutral | |
| $0.9676 | $1.21 | $1.61 | -2% | Neutral | |
| $0.994 | $1.28 | $1.75 | +3% | Neutral | |
| $1.16 | $1.52 | $2.14 | +23% | Bullish | |
| $1.12 | $1.51 | $2.17 | +21% | Bullish | |
| $1.10 | $1.50 | $2.21 | +21% | Bullish | |
| $1.11 | $1.53 | $2.29 | +24% | Bullish | |
| $1.03 | $1.45 | $2.21 | +17% | Neutral | |
| $1.18 | $1.67 | $2.59 | +35% | Bullish | |
| $1.36 | $1.97 | $3.08 | +59% | Bullish | |
| $1.52 | $2.33 | $3.86 | +88% | Bullish | |
| $2.20 | $3.76 | $6.80 | +203% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.08 | $1.24 | $1.46 | +0.00% |
| June 2026 | $1.08 | $1.26 | $1.52 | +1.85% |
| July 2026 | $1.04 | $1.23 | $1.49 | -2.73% |
| August 2026 | $1.03 | $1.23 | $1.51 | +0.03% |
| September 2026 | $1.04 | $1.25 | $1.54 | +1.63% |
| October 2026 | $1.01 | $1.22 | $1.51 | -2.63% |
| November 2026 | $0.9803 | $1.18 | $1.48 | -2.77% |
| December 2026 | $0.9987 | $1.21 | $1.53 | +2.28% |
Click any year to see its month-by-month BBLG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BBLG is projected to trade between $1.08 and $1.53, averaging $1.24 — a potential gain of 0% from today's $1.24. Price action looks broadly range-bound.
Bone Biologics Corporation's 2027 outlook centres on $1.21, within a $0.9676 to $1.61 range. That is -2% versus the projected 2026 average. That marks a -2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, BBLG could reach as high as $1.75, with a base case around $1.28 and support toward $0.994 — roughly +3% from $1.24. Price action looks broadly range-bound.
Expect BBLG to range from $1.16 to $2.14 through 2029. The $1.52 average target implies a +23% move from current prices. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BBLG price prediction for 2030 points to an average of $1.51 (low $1.12, high $2.17) — a potential gain of +21% on today's $1.24. Momentum favours further upside here.
In 2031, BBLG is projected to trade between $1.10 and $2.21, averaging $1.50 — a potential gain of +21% from today's $1.24. That is 0% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Bone Biologics Corporation's 2032 outlook centres on $1.53, within a $1.11 to $2.29 range. That is up +2% on the projected 2031 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2033, BBLG could reach as high as $2.21, with a base case around $1.45 and support toward $1.03 — roughly +17% from $1.24. A consolidation phase looks the most probable path here.
Expect BBLG to range from $1.18 to $2.59 through 2034. The $1.67 average target implies a +35% move from current prices. That is up +15% on the projected 2033 average. Momentum favours further upside here.
The BBLG price prediction for 2035 points to an average of $1.97 (low $1.36, high $3.08) — a potential gain of +59% on today's $1.24. Buyers look set to stay in control over this stretch.
In 2040, BBLG is projected to trade between $1.52 and $3.86, averaging $2.33 — a potential gain of +88% from today's $1.24. That is up +18% on the projected 2035 average. Momentum favours further upside here.
Bone Biologics Corporation's 2050 outlook centres on $3.76, within a $2.20 to $6.80 range. That is up +62% on the projected 2040 average. That marks a +203% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BBLG today (≈ 806.451613 BBLG) could be worth
$3,032.63
+$2,032.63 (+203%) by 2050 · US Dollar
Based on the average projected BBLG price of $3.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBLGwould be worth at today's price.
$1,000 invested in BBLG on May 27, 2025 (≈ 198.4127 BBLG) would be worth
$246.03
-$753.97 (-75.4%) today · 0.25× · US Dollar
Based on a BBLG entry price of $5.04 vs. today's $1.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.23 | $1,008.13 | +0.8% |
| 1 month ago | $1.38 | $898.55 | -10.1% |
| 3 months ago | $1.15 | $1,078.26 | +7.8% |
| 6 months ago | $1.5 | $826.67 | -17.3% |
| 1 year ago | $5.04 | $246.03 | -75.4% |
| All time (4.6y) ago | $7,329.6 | $0.17 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBLG forecast.
Our base-case forecast reaches $2.50 around 2050.
Implied market cap at $2.50: $4.49M
The multi-year forecast shows a path from neutral into bullish territory in the later years, with 2026 to 2028 mostly neutral and 2029 onward more bullish. The 2026 avg is $1.22 with ROI 0 and sentiment NEUTRAL; 2027 avg $1.18 with ROI -3 and NEUTRAL; 2028 avg $1.24 with ROI 1.8 and NEUTRAL. The outlook strengthens into 2029 (avg $1.49, ROI 22.1, BULLISH) and 2030 (avg $1.46, ROI 20.1, BULLISH), continuing through 2032 (avg $1.50, ROI 22.6, BULLISH) and 2034 (avg $1.62, ROI 32.8, BULLISH).
By 2035 the forecast shows avg $1.92 with ROI 57.4 and BULLISH, and later years remain bullish with 2040 avg $2.24 (ROI 83.8) and 2050 avg $3.64 (ROI 198). The 2030, 2040, and 2050 results point to higher potential upside, including a max price forecast up to $2.12 in 2030, $3.74 in 2040, and $6.61 in 2050. These figures are estimates and not guarantees; actual results may vary.
Tap a question to reveal the answer.
2030: min $1.09, avg $1.46, max $2.12; ROI 20.1; sentiment BULLISH.
The year-by-year forecast shows a mix of neutral and bullish periods, with negative ROI in 2027 (-3) and positive returns in later years (e.g., 2029 22.1, 2030 20.1, 2040 83.8, 2050 198). These are estimates and not guarantees.
Yes, the max forecast by 2050 is $6.61, and the 2040 max is $3.74, indicating potential upside beyond $5 later in the horizon.
Current price is $1.22 and market cap is $2.19M.
Bearish sentiment with RSI 40. Price trades below SMA50 ($1.26) and below SMA200 ($1.72). Support is $1.22 and resistance is $1.40, with a 30-day range of $1.03 to $1.45.
Bone Biologics Corporation Community Discussion
0Share your Bone Biologics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.